176 related articles for article (PubMed ID: 32320750)
1. The molecular functions of common and atypical MLL fusion protein complexes.
Takahashi S; Yokoyama A
Biochim Biophys Acta Gene Regul Mech; 2020 Jul; 1863(7):194548. PubMed ID: 32320750
[TBL] [Abstract][Full Text] [Related]
2. MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment.
Ugale A; Säwén P; Dudenhöffer-Pfeifer M; Wahlestedt M; Norddahl GL; Bryder D
Oncogene; 2017 Jun; 36(22):3207-3212. PubMed ID: 28068328
[TBL] [Abstract][Full Text] [Related]
3. The reciprocal world of MLL fusions: A personal view.
Marschalek R
Biochim Biophys Acta Gene Regul Mech; 2020 Jul; 1863(7):194547. PubMed ID: 32294539
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional activation by MLL fusion proteins in leukemogenesis.
Yokoyama A
Exp Hematol; 2017 Feb; 46():21-30. PubMed ID: 27865805
[TBL] [Abstract][Full Text] [Related]
5. The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription.
Mak AB; Nixon AM; Moffat J
Cancer Res; 2012 Apr; 72(8):1929-34. PubMed ID: 22337994
[TBL] [Abstract][Full Text] [Related]
6. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia.
Okuda H; Stanojevic B; Kanai A; Kawamura T; Takahashi S; Matsui H; Takaori-Kondo A; Yokoyama A
J Clin Invest; 2017 May; 127(5):1918-1931. PubMed ID: 28394257
[TBL] [Abstract][Full Text] [Related]
7. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes.
Biswas D; Milne TA; Basrur V; Kim J; Elenitoba-Johnson KS; Allis CD; Roeder RG
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15751-6. PubMed ID: 21896721
[TBL] [Abstract][Full Text] [Related]
8. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.
Osaki H; Walf-Vorderwülbecke V; Mangolini M; Zhao L; Horton SJ; Morrone G; Schuringa JJ; de Boer J; Williams O
Leukemia; 2013 Jul; 27(7):1461-8. PubMed ID: 23403462
[TBL] [Abstract][Full Text] [Related]
9. Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia.
Zhang Y; Owens K; Hatem L; Glass CH; Karuppaiah K; Camargo F; Perkins AS
Blood; 2013 Oct; 122(16):2888-92. PubMed ID: 24021671
[TBL] [Abstract][Full Text] [Related]
10. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of MLL-associated leukemia.
Yokoyama A
Int J Hematol; 2015 Apr; 101(4):352-61. PubMed ID: 25773519
[TBL] [Abstract][Full Text] [Related]
12. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.
Monroe SC; Jo SY; Sanders DS; Basrur V; Elenitoba-Johnson KS; Slany RK; Hess JL
Exp Hematol; 2011 Jan; 39(1):77-86.e1-5. PubMed ID: 20854876
[TBL] [Abstract][Full Text] [Related]
13. Learning from mouse models of MLL fusion gene-driven acute leukemia.
Schwaller J
Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194550. PubMed ID: 32320749
[TBL] [Abstract][Full Text] [Related]
14. Structure of AF3p21, a new member of mixed lineage leukemia (MLL) fusion partner proteins-implication for MLL-induced leukemogenesis.
Sano K
Leuk Lymphoma; 2001 Aug; 42(4):595-602. PubMed ID: 11697487
[TBL] [Abstract][Full Text] [Related]
15. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
16. circRNA circAF4 functions as an oncogene to regulate MLL-AF4 fusion protein expression and inhibit MLL leukemia progression.
Huang W; Fang K; Chen TQ; Zeng ZC; Sun YM; Han C; Sun LY; Chen ZH; Yang QQ; Pan Q; Luo XQ; Wang WT; Chen YQ
J Hematol Oncol; 2019 Oct; 12(1):103. PubMed ID: 31623653
[TBL] [Abstract][Full Text] [Related]
17. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.
Bursen A; Schwabe K; Rüster B; Henschler R; Ruthardt M; Dingermann T; Marschalek R
Blood; 2010 Apr; 115(17):3570-9. PubMed ID: 20194896
[TBL] [Abstract][Full Text] [Related]
18. A Transcription Factor Addiction in Leukemia Imposed by the MLL Promoter Sequence.
Lu B; Klingbeil O; Tarumoto Y; Somerville TDD; Huang YH; Wei Y; Wai DC; Low JKK; Milazzo JP; Wu XS; Cao Z; Yan X; Demerdash OE; Huang G; Mackay JP; Kinney JB; Shi J; Vakoc CR
Cancer Cell; 2018 Dec; 34(6):970-981.e8. PubMed ID: 30503706
[TBL] [Abstract][Full Text] [Related]
19. MLL-ENL leukemia burden initiated in femoral diaphysis and preceded by mature B-cell depletion.
Jaracz-Ros A; Lewandowski D; Barroca V; Lavau C; Roméo PH
Haematologica; 2011 Dec; 96(12):1770-8. PubMed ID: 21933859
[TBL] [Abstract][Full Text] [Related]
20. HBO1-MLL interaction promotes AF4/ENL/P-TEFb-mediated leukemogenesis.
Takahashi S; Kanai A; Okuda H; Miyamoto R; Komata Y; Kawamura T; Matsui H; Inaba T; Takaori-Kondo A; Yokoyama A
Elife; 2021 Aug; 10():. PubMed ID: 34431785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
